Exhibit A Exhibit A Exhibit B Exhibit B Exhibit C Exhibit C Migraines affect over 37 million Americans, according to…
Data presented at the Society of NeuroOncology (SNO) 28th Annual MeetingBerubicin currently being evaluated in an ongoing potentially pivotal study…
MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies…
– Fast Track Designation accelerates ADP101's development path for the treatment of mono- and multi-food allergy – – Phase 1/2…
SYDNEY, AUSTRALIA, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage…
SAN MATEO, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing…
Grant of Its Newest U.S. Patent Expands Anavex’s Compounds Intellectual Property PortfolioNEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Anavex…
Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s…
NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…
VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:…